| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/12/2023 | 182.07% | Roth MKM | → $31 | Reiterates | Buy → Buy |
| 08/16/2023 | 182.07% | Roth MKM | → $31 | Reiterates | Buy → Buy |
| 04/06/2023 | 36.49% | Oppenheimer | → $15 | Initiates Coverage On | → Outperform |
| 09/30/2022 | 104.73% | Canaccord Genuity | → $22.5 | Initiates Coverage On | → Buy |
| 10/08/2021 | 91.08% | Roth Capital | → $21 | Initiates Coverage On | → Buy |
| 03/15/2021 | 36.49% | Lake Street | → $15 | Initiates Coverage On | → Buy |
What is the target price for Bioceres Crop Solutions (BIOX)?
The latest price target for Bioceres Crop Solutions (NASDAQ: BIOX) was reported by Roth MKM on September 12, 2023. The analyst firm set a price target for $31.00 expecting BIOX to rise to within 12 months (a possible 182.07% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bioceres Crop Solutions (BIOX)?
The latest analyst rating for Bioceres Crop Solutions (NASDAQ: BIOX) was provided by Roth MKM, and Bioceres Crop Solutions reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Bioceres Crop Solutions (BIOX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioceres Crop Solutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioceres Crop Solutions was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.
Is the Analyst Rating Bioceres Crop Solutions (BIOX) correct?
While ratings are subjective and will change, the latest Bioceres Crop Solutions (BIOX) rating was a reiterated with a price target of $0.00 to $31.00. The current price Bioceres Crop Solutions (BIOX) is trading at is $10.99, which is within the analyst's predicted range.